The author is in the Department of Physiology, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois 60153, USA. dbers@lumc.edu
Blocking -adrenergic receptors is a standard treatment for heart failure, but it limits the normal ability to modulate cardiac function. Targeting therapy further downstream by blocking activation of calcium-calmodulin−dependent protein kinase could provide an alternative (pages 409−407).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
-adrenergic receptors is a standard treatment for heart failure, but it limits the normal ability to modulate cardiac function. Targeting therapy further downstream by blocking activation of calcium-calmodulin−dependent protein kinase could provide an alternative (pages 409−407).
